Emerging research from a 2026 study transforms our understanding of sex-specific immune responses in cancer by spotlighting the critical enzyme DGAT1 in CD8+ T cells. While fatty acid (FA) oxidation has been extensively studied for its role in T cell activity, this breakthrough exposes the nuanced functions of DGAT1-mediated fatty acid esterification to triacylglycerol (TAG) within the tumor microenvironment. This novel insight reveals how DGAT1 drives distinct immune behaviors between female and male hosts, unlocking potential avenues for sex-specific immunotherapies and targeted metabolic interventions in cancer treatment.
The study reveals a fascinating sexual dimorphism in T cell metabolism. In female mice, the deletion of the Dgat1 gene in T cells sharply improves mitochondrial metabolic capacity, promoting the expansion of a pool of progenitor exhausted CD8+ T (Tex) cells. These Tex cells, although functionally restrained to prevent autoimmunity, are vital in sustaining long-term antitumor immunity. Hence, DGAT1 deficiency in female T cells bolsters the immune response by enhancing their mitochondrial function and survival, which may translate to improved therapeutic outcomes in female cancer patients.
Contrastingly, the scenario in male mice paints a starkly different picture. Loss of DGAT1 in male CD8+ Tex cells results in a cascade of detrimental events, including excessive fatty acid peroxidation and intensified endoplasmic reticulum (ER) stress. These pathological changes culminate in increased Tex cell death, undermining antitumor immunity. This sex-dependent divergence in T cell fate underlying DGAT1 loss is unexpected and points to a complex interplay between lipid metabolism and immune stress responses that is modulated by biological sex.
Central to this male-specific vulnerability is androgen receptor (AR) signaling, a well-known regulator of male physiology. The researchers demonstrate that AR activation exacerbates oxidative damage and ER stress in DGAT1-deficient male T cells. This regulatory axis suggests that androgen signaling intertwines with metabolic pathways in T cells to dictate cell survival and function, uniquely sensitizing male immune cells to disruptions in lipid handling mechanisms. This finding bridges endocrinology and immunometabolism, proposing AR as a key modulatory node.
Intriguingly, genetic deletion of the Ar gene in male mice rescues the heightened Tex cell death phenotype induced by Dgat1 deficiency. This genetic manipulation stabilizes mitochondrial fitness and lowers ER stress markers, effectively restoring the antitumor potential of male Tex cells. These results reveal that targeting AR signaling can mitigate metabolic stress under conditions of compromised DGAT1 activity, highlighting a promising therapeutic target to equalize immune competence across sexes.
Further investigation reveals that overexpression of glutathione peroxidase 4 (GPX4), a critical enzyme preventing lipid peroxidation, also protects DGAT1-deficient male CD8+ T cells. By reducing harmful lipid peroxides, GPX4 alleviates oxidative insults, curbing the ER stress response that triggers cell death. This observation emphasizes the central role of oxidative damage in dictating the survival of male T cells in the absence of DGAT1 and presents antioxidant strategies as viable approaches to enhance immunosurveillance.
Moreover, pharmacological inhibition of ER stress-induced apoptotic pathways shows therapeutic promise by rescuing male DGAT1-deficient T cell populations. Blocking these cell death cascades preserves the functional Tex cell reservoir crucial for sustained tumor control. These findings collectively underscore a multifaceted network regulating T cell fate, where lipid metabolism, oxidative stress, ER homeostasis, and sex hormone signaling converge to shape immune responses in cancer.
At the mechanistic level, DGAT1 enzymatic activity detoxifies fatty acids by converting them into inert triacylglycerol stores within lipid droplets. This storage mechanism buffers the cytotoxic effects of free fatty acids and their oxidized derivatives. In male CD8+ T cells, this detoxification is indispensable given the heightened androgen-driven metabolic demands and stress responses. The lack of DGAT1 thus leaves male T cells vulnerable to lipotoxicity, impairing their persistence and function within the tumor microenvironment.
Conversely, female T cells appear metabolically adapted to thrive despite DGAT1 loss, potentially due to lower basal AR signaling or alternative compensatory pathways enhancing mitochondrial resilience. This sex-specific metabolic plasticity may inform why females often exhibit stronger immune responses and better outcomes in certain cancers, highlighting an intrinsic biological disparity molded by hormonal and metabolic factors.
The implications of this study stretch beyond basic immunology. By uncovering how metabolic reprogramming interlaces with sex hormone signaling to affect T cell fate, the research advocates for personalized, sex-informed strategies in cancer immunotherapy. Such approaches could optimize metabolic targets like DGAT1, GPX4, or AR pathways to enhance CD8+ Tex cell function according to patient sex, ultimately improving therapeutic efficacy and minimizing adverse effects.
This work also prompts reevaluation of current clinical paradigms that overlook sex differences in immune metabolism. Incorporating sex as a biological variable in preclinical and clinical studies could unmask hidden mechanisms influencing therapy responses and disease progression, thereby driving precision medicine forward.
Looking forward, deeper exploration into how other immune subsets and metabolic enzymes participate in sex-dependent tumor immunity will be critical. Understanding the full landscape of interactions between lipid metabolism, cellular stress, and hormonal regulation could uncover additional vulnerabilities amenable to pharmacological intervention.
In conclusion, the study illuminates a hitherto unrecognized sexually dimorphic axis in T cell metabolism mediated by DGAT1 and androgen receptor signaling. This nuanced metabolic control governs the balance between antitumor immunity and immune exhaustion, with profound consequences for cancer progression and treatment. By integrating metabolic enzymology, immune cell biology, and endocrinology, this research heralds a new era of sex-specific cancer immunotherapy grounded in fundamental biology.
Subject of Research: Sex-specific metabolic adaptations in CD8+ tumor-infiltrating lymphocytes mediated by DGAT1 and androgen receptor signaling in antitumor responses.
Article Title: DGAT1 mediates sex-specific CD8+ T cell antitumour responses.
Article References:
Madi, A., Shi, H., Su, M. et al. DGAT1 mediates sex-specific CD8+ T cell antitumour responses. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01462-7
Image Credits: AI Generated
